StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.57+0.07 (+0.67%)

Close on Nov 19, 2026Market cap $8.43BP/E –Yield –

Summit Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Summit Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0. For fiscal 2024 it was $0. The highest annual figure on record is $57.09M in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2024Dec 31, 2024$0–
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$705.00K-61.0%
FY2021Dec 31, 2021$1.81M-96.8%
FY2019Jan 31, 2019$57.09M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2024CQ4 2024Dec 31, 2024$0–
Q3 FY2024CQ3 2024Sep 30, 2024$0–
Q4 FY2023CQ4 2023Dec 31, 2023$0–
Q3 FY2023CQ3 2023Sep 30, 2023$0-100.0%
Q2 FY2023CQ2 2023Jun 30, 2023$0-100.0%
Q1 FY2023CQ1 2023Mar 31, 2023$0-100.0%
Q4 FY2022CQ4 2022Dec 31, 2022$0-100.0%
Q3 FY2022CQ3 2022Sep 30, 2022$220.00K-83.2%
Q2 FY2022CQ2 2022Jun 30, 2022$235.00K+312.3%
Q1 FY2022CQ1 2022Mar 31, 2022$250.00K+30.2%
Q4 FY2021CQ4 2021Dec 31, 2021$251.00K–
Q3 FY2021CQ3 2021Sep 30, 2021$1.31M–
Q2 FY2021CQ2 2021Jun 30, 2021$57.00K–
Q1 FY2021CQ1 2021Mar 31, 2021$192.00K–

More Summit Therapeutics figures

See a number that looks wrong?